Get the Stockscreener App
0.744
0.21%
-0.0016
Briacell Therapeutics Corp stock is traded at $0.744, with a volume of 632.75K.
It is down -0.21% in the last 24 hours and down -73.99% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.7456
Open:
$0.725
24h Volume:
632.75K
Relative Volume:
0.56
Market Cap:
$13.06M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-0.836
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-6.93%
1M Performance:
-73.99%
6M Performance:
-85.18%
1Y Performance:
-93.16%
1-Day Range:
$0.71
$0.7566
1-Week Range:
$0.71
$0.82
52-Week Range:
$0.69
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.744 | 13.09M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - jammulinksnews.com
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockBreakout Stocks Insights To Watch Now - jammulinksnews.com
Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockStock Market Ideas With Proven Results - jammulinksnews.com
What institutional investors are buying BriaCell Therapeutics Corp. stockTop Growth Tracker With Low Risk - jammulinksnews.com
BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks
UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com South Africa
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire
FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan
Foraco International reports Q2 2025 - The Globe and Mail
WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail
BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa
BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com
Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it
BriaCell Secures New Zealand Patent for Cancer Immunotherapy - TipRanks
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire
BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment - Stock Titan
Published on: 2025-07-30 10:30:41 - metal.it
Is BriaCell Therapeutics Corp. Equity Warrant a Top Dividend Stock to Watch in 2025 - metal.it
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents - GlobeNewswire
BriaCell Therapeutics Corp. Recovery Linked to Earnings SurpriseDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-29 17:12:14 - metal.it
BriaCell Therapeutics Corp. Equity Warrant Recovers — But Is It SustainableReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform - TipRanks
Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan
Why did BCTX report zero EPS for Q3 2023? - AInvest
Published on: 2025-07-29 07:17:26 - metal.it
What are analysts’ price targets for BriaCell Therapeutics Corp. in the next 12 monthsEarnings Report Insights With Low Risk - jammulinksnews.com
How does BriaCell Therapeutics Corp. generate profit in a changing economyCapitalize on proven investment strategies - jammulinksnews.com
What are the technical indicators suggesting about BriaCell Therapeutics Corp.Build a portfolio that outperforms the market - jammulinksnews.com
What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Build wealth faster with expert stock selection - jammulinksnews.com
Applying Wyckoff theory to BriaCell Therapeutics Corp. stock Free Oversold Recovery Opportunity Stocks - metal.it
What are BriaCell Therapeutics Corp. company’s key revenue driversExceptional market positioning - jammulinksnews.com
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. stockExpert Picks Watchlist For 2025 - jammulinksnews.com
Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Consistent wealth multiplication - jammulinksnews.com
What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Achieve consistent profits with smart trading - jammulinksnews.com
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economyCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedGet daily expert analysis on top stocks - jammulinksnews.com
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stock - jammulinksnews.com
How volatile is BriaCell Therapeutics Corp. stock compared to the marketAchieve breakthrough investment performance - jammulinksnews.com
When is BriaCell Therapeutics Corp. Equity Warrant stock expected to show significant growth - jammulinksnews.com
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockBuild wealth with long-term growth strategies - jammulinksnews.com
What makes BriaCell Therapeutics Corp. stock price move sharplyMaximize returns with timely market signals - jammulinksnews.com
Why BriaCell Therapeutics Corp. stock is on top investor watchlistsFree Capital Allocation Plans - metal.it
How does BriaCell Therapeutics Corp. compare to its industry peersInvest like a pro with expert recommendations - jammulinksnews.com
How BriaCell Therapeutics Corp. Equity Warrant stock performs during market volatilityProven Win Setups - metal.it
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):